Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced that 1,000 patients have now been treated with Percutaneous Transmural Arterial Bypass (PTAB) using the DETOUR System. This milestone includes patients in the DETOUR1 and DETOUR2 clinical studies as well as those treated post-commercial launch (July 2023).
Health Technology Insights: Circular Genomics Adds Alzheimer’s Expert to Scientific Advisory Board
PTAB with the DETOUR System offers a novel approach to treating complex peripheral arterial disease (PAD), enabling physicians to percutaneously bypass lesions in the superficial femoral artery by using stents routed through the femoral vein to restore blood flow to the leg. The DETOUR System is comprised of the ENDOCROSS device and TORUS stent grafts, providing a minimally invasive alternative to surgical bypass.
“Reaching 1,000 patients treated with the DETOUR System is a significant achievement, demonstrating the growing adoption of PTAB as an important option for patients with complex femoropopliteal disease,” said Andrew Davis, Chief Commercial Officer at Endologix. “This milestone underscores our commitment to expanding access to innovative treatments that improve patient outcomes while reducing the need for more invasive procedures.”
Health Technology Insights: Proscia Raises $50MILLION to Advance Ai-Driven Pathology and Precision Medicine
Upon successfully treating the 1,000th patient on Friday, Dr. Sheraz Qureshi from Northwestern Medicine Central DuPage Hospital remarked: “Reaching the 1,000th patient milestone is a testament to the real-world impact this therapy is having. For patients with long SFA disease, this approach is offering a new pathway to better outcomes, improved mobility, and an overall better quality of life”
The DETOUR System has been studied extensively in clinical trials, with results highlighting its durability, safety, and efficacy. The DETOUR2 study, which enrolled 202 patients across 32 sites, demonstrated strong long-term outcomes comparable to open surgical bypass while reducing the length of stay and minimizing the complications associated with open bypass surgery. Post-market adoption continues to show positive real-world performance, reinforcing the role of PTAB with the DETOUR System in the treatment paradigm for complex PAD.
Health Technology Insights: Tech Mahindra and Nvidia Advance Drug Safety With Ai-Powered Solution
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
